HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages.
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio is a clinical stage private company developing advanced products to treat and prevent cancer and infectious diseases. Utilizing our proprietary LION™ technology, our products feature superior safety, potency, durability, and manufacturing advantages
HDT Bio’s proprietary technologies harness the immune system to combat difficult-to-treat conditions and improve patient lives worldwide.
The next generation of formulations
HDT’s LION™ technology provides increased potency compared to traditional formulations – increasing safety, tolerability, immunogenicity, and manufacturability.
Latest News
Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
Click here to view article
A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
SEATTLE, May 21, 2026 /PRNewswire/ -- HDT Bio, a clinical-stage biotechnology company based in Seattle, Washington, today announced that it received the Medical CBRN Defense Consortium (MCDC) Innovation Prototype Award. The award recognizes HDT Bio's MCDC project...